Revolution Medicines Reports Positive Clinical Data for Daraxonrasib
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 19 2026
0mins
Should l Buy RVMD?
Revolution Medicines Inc. shares rose by 9.36% as the stock crossed above its 5-day SMA, reflecting positive investor sentiment following the release of updated clinical data on daraxonrasib. The company presented promising results at the AACR Annual Meeting, showing that daraxonrasib demonstrated manageable safety and early signs of durable antitumor activity in patients with metastatic pancreatic ductal adenocarcinoma. This data supports further evaluation of daraxonrasib in first-line treatment, with combination therapy achieving a 58% objective response rate and monotherapy showing a 47% response rate, indicating strong potential for the drug in treating challenging cancers. The implications of these results could enhance Revolution Medicines' competitive position in oncology and attract further investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RVMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RVMD
Wall Street analysts forecast RVMD stock price to fall
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 144.120
Low
67.00
Averages
86.00
High
147.00
Current: 144.120
Low
67.00
Averages
86.00
High
147.00
About RVMD
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves Revolution Medicines' Cancer Therapy for Expanded Access
- New Therapy Approval: The FDA has granted Revolution Medicines permission to provide its investigational therapy daraxonrasib to pancreatic cancer patients outside of clinical trials, marking a significant advancement in cancer treatment.
- Targeted Treatment Innovation: Daraxonrasib is designed to target cancer-causing mutations in the RAS gene family, representing a new class of cancer therapies that may offer new treatment options for patients with metastatic pancreatic ductal adenocarcinoma.
- Clinical Data Support: The therapy has shown promising results in late-stage trials, and Revolution Medicines plans to submit a marketing application seeking expedited review for daraxonrasib, further advancing its commercialization efforts.
- Significant Market Potential: By implementing the expanded access treatment protocol, Revolution Medicines can provide daraxonrasib to metastatic PDAC patients in a controlled setting, which is expected to significantly enhance the company's competitiveness in the cancer treatment market.
See More
Erasca's Cancer Drug Trial Data Triggers Stock Plunge
- Trial Data Release: Erasca (ERAS) released early data from its Phase 1 trial for the solid tumor candidate ERAS-0015, resulting in a ~37% drop in stock price during after-hours trading, indicating market concerns about its clinical prospects.
- Safety Concerns: While ERAS-0015 demonstrated a well-tolerated safety profile in trials in the U.S. and China, the company disclosed a fatality of a heavily pre-treated pancreatic cancer patient who died after receiving a 24 mg dose, highlighting potential safety risks.
- Efficacy Data: The biotech reported unconfirmed overall response rates (uORR) of 62% and 40% among patients with KRAS G12X non-small cell lung cancer and pancreatic cancer, respectively, based on patients receiving 16-32 mg QD, suggesting some efficacy potential.
- Patent Dispute: Erasca revealed a potential patent dispute with rival Revolution Medicines (RVMD), which alleged that ERAS-0015 infringed its U.S. Patent No. 12,409,225, while Erasca stated it intends to contest these claims vigorously, demonstrating its strong stance on intellectual property.
See More
Erasca's Cancer Therapy Trial Reports Treatment-Related Death
- Treatment-Related Death: In Erasca's ERAS-0015 clinical trial, a 66-year-old pancreatic cancer patient developed Grade 3 pneumonitis after receiving a 24 mg dose, leading to death, which was buried in safety disclosures and caused the company's stock to plunge nearly 40% in after-hours trading.
- Early Tumor Response Rates: Despite the death, Erasca reported a 62% tumor response rate for ERAS-0015 in KRAS-mutant non-small cell lung cancer patients, rising to 75% among those previously treated with immunotherapy and platinum chemotherapy, indicating the therapy's potential efficacy.
- Future Data Expectations: Erasca anticipates additional data from the Auroras-1 trial in 2027, while preliminary data for its other candidate, ERAS-4001, is expected later this year, which could significantly impact the company's strategic direction and investor confidence.
- Increased Legal Pressure: Erasca disclosed receiving a letter from Revolution Medicines alleging that ERAS-0015 may infringe on U.S. patent claims, requesting the company to cease production and sales, which could further pressure the company's market outlook and stock price.
See More
Revolution Medicines Stock Soars 250% Despite No Revenue
- Stock Performance: Revolution Medicines' shares have surged over 250% in the past year, with a market cap nearing $30 billion, despite the company currently being unprofitable and generating no revenue, indicating high market expectations for future growth.
- Promising Drugs: Although the company lacks approved products, its drug daraxonrasib shows significant potential in treating pancreatic cancer, with clinical studies indicating a median survival extension from 6.7 months to 13.2 months, suggesting high future sales potential.
- Market Expectations: Analysts project that daraxonrasib could peak at over $7 billion in sales, and additional cancer drugs like zoldonrasib and elironrasib may generate billions more, making the current high valuation appear more justifiable in light of potential growth.
- Investment Risks: While there is considerable excitement around Revolution Medicines, investors should be cautious as the current stock price may reflect excessive future growth expectations, with uncertainties regarding cash flow, drug approvals, and market competition posing risks of significant price volatility.
See More
Revolution Medicines' Promising Drug Sparks Investor Excitement
- Clinical Trial Results: Revolution Medicines' new drug daraxonrasib has significantly extended the survival of pancreatic cancer patients in clinical trials, with chemotherapy patients averaging 6.7 months of survival compared to 13.2 months for those on daraxonrasib, establishing a strong foundation for the company's future market potential.
- Market Potential Assessment: Analysts project that daraxonrasib's peak sales could exceed $7 billion, and with additional cancer drugs like zoldonrasib and elironrasib potentially generating billions more, the company's high valuation may appear more justified in light of this growth potential.
- Investment Risk Warning: While investor enthusiasm for Revolution Medicines' stock is high, caution is advised regarding overly optimistic future growth expectations, as the current valuation lacks a margin of safety, posing a risk of significant stock price declines if any issues arise.
- Industry Competition Analysis: Despite the excitement surrounding the stock, Revolution Medicines was not included in The Motley Fool Stock Advisor's list of the top 10 stocks to buy, indicating ongoing uncertainty about its future performance in a competitive market.
See More
Revolution Medicines Updates Clinical Data on Daraxonrasib for Pancreatic Cancer
- Clinical Trial Update: Revolution Medicines has updated clinical data from two Phase 1/2 trials of Daraxonrasib in previously untreated metastatic pancreatic ductal adenocarcinoma patients, demonstrating manageable safety and tolerability, supporting further evaluation in first-line treatment.
- Combination Therapy Results: In the RMC-GI-102 trial, patients receiving Daraxonrasib combined with gemcitabine and nab-paclitaxel showed a confirmed objective response rate (ORR) of 58%, indicating significant antitumor activity, with a 6-month progression-free survival (PFS) estimate of 84%.
- Monotherapy Performance: In the RMC-6236-001 trial, Daraxonrasib monotherapy yielded an ORR of 47% and a disease control rate of 92%, with a 6-month PFS estimate of 71%, highlighting its potential in treating previously untreated RAS-mutant metastatic pancreatic cancer patients.
- Future Presentation Plans: The company plans to present the latest data from both the combination and monotherapy cohorts at the American Association for Cancer Research Annual Meeting on April 21, 2026, further validating the application prospects of Daraxonrasib in this high-mortality cancer.
See More
FDA Approves Revolution Medicines' Cancer Therapy for Expanded Access
- New Therapy Approval: The FDA has granted Revolution Medicines permission to provide its investigational therapy daraxonrasib to pancreatic cancer patients outside of clinical trials, marking a significant advancement in cancer treatment.
- Targeted Treatment Innovation: Daraxonrasib is designed to target cancer-causing mutations in the RAS gene family, representing a new class of cancer therapies that may offer new treatment options for patients with metastatic pancreatic ductal adenocarcinoma.
- Clinical Data Support: The therapy has shown promising results in late-stage trials, and Revolution Medicines plans to submit a marketing application seeking expedited review for daraxonrasib, further advancing its commercialization efforts.
- Significant Market Potential: By implementing the expanded access treatment protocol, Revolution Medicines can provide daraxonrasib to metastatic PDAC patients in a controlled setting, which is expected to significantly enhance the company's competitiveness in the cancer treatment market.
See More
Erasca's Cancer Drug Trial Data Triggers Stock Plunge
- Trial Data Release: Erasca (ERAS) released early data from its Phase 1 trial for the solid tumor candidate ERAS-0015, resulting in a ~37% drop in stock price during after-hours trading, indicating market concerns about its clinical prospects.
- Safety Concerns: While ERAS-0015 demonstrated a well-tolerated safety profile in trials in the U.S. and China, the company disclosed a fatality of a heavily pre-treated pancreatic cancer patient who died after receiving a 24 mg dose, highlighting potential safety risks.
- Efficacy Data: The biotech reported unconfirmed overall response rates (uORR) of 62% and 40% among patients with KRAS G12X non-small cell lung cancer and pancreatic cancer, respectively, based on patients receiving 16-32 mg QD, suggesting some efficacy potential.
- Patent Dispute: Erasca revealed a potential patent dispute with rival Revolution Medicines (RVMD), which alleged that ERAS-0015 infringed its U.S. Patent No. 12,409,225, while Erasca stated it intends to contest these claims vigorously, demonstrating its strong stance on intellectual property.
See More
Erasca's Cancer Therapy Trial Reports Treatment-Related Death
- Treatment-Related Death: In Erasca's ERAS-0015 clinical trial, a 66-year-old pancreatic cancer patient developed Grade 3 pneumonitis after receiving a 24 mg dose, leading to death, which was buried in safety disclosures and caused the company's stock to plunge nearly 40% in after-hours trading.
- Early Tumor Response Rates: Despite the death, Erasca reported a 62% tumor response rate for ERAS-0015 in KRAS-mutant non-small cell lung cancer patients, rising to 75% among those previously treated with immunotherapy and platinum chemotherapy, indicating the therapy's potential efficacy.
- Future Data Expectations: Erasca anticipates additional data from the Auroras-1 trial in 2027, while preliminary data for its other candidate, ERAS-4001, is expected later this year, which could significantly impact the company's strategic direction and investor confidence.
- Increased Legal Pressure: Erasca disclosed receiving a letter from Revolution Medicines alleging that ERAS-0015 may infringe on U.S. patent claims, requesting the company to cease production and sales, which could further pressure the company's market outlook and stock price.
See More
Revolution Medicines Stock Soars 250% Despite No Revenue
- Stock Performance: Revolution Medicines' shares have surged over 250% in the past year, with a market cap nearing $30 billion, despite the company currently being unprofitable and generating no revenue, indicating high market expectations for future growth.
- Promising Drugs: Although the company lacks approved products, its drug daraxonrasib shows significant potential in treating pancreatic cancer, with clinical studies indicating a median survival extension from 6.7 months to 13.2 months, suggesting high future sales potential.
- Market Expectations: Analysts project that daraxonrasib could peak at over $7 billion in sales, and additional cancer drugs like zoldonrasib and elironrasib may generate billions more, making the current high valuation appear more justifiable in light of potential growth.
- Investment Risks: While there is considerable excitement around Revolution Medicines, investors should be cautious as the current stock price may reflect excessive future growth expectations, with uncertainties regarding cash flow, drug approvals, and market competition posing risks of significant price volatility.
See More
Revolution Medicines' Promising Drug Sparks Investor Excitement
- Clinical Trial Results: Revolution Medicines' new drug daraxonrasib has significantly extended the survival of pancreatic cancer patients in clinical trials, with chemotherapy patients averaging 6.7 months of survival compared to 13.2 months for those on daraxonrasib, establishing a strong foundation for the company's future market potential.
- Market Potential Assessment: Analysts project that daraxonrasib's peak sales could exceed $7 billion, and with additional cancer drugs like zoldonrasib and elironrasib potentially generating billions more, the company's high valuation may appear more justified in light of this growth potential.
- Investment Risk Warning: While investor enthusiasm for Revolution Medicines' stock is high, caution is advised regarding overly optimistic future growth expectations, as the current valuation lacks a margin of safety, posing a risk of significant stock price declines if any issues arise.
- Industry Competition Analysis: Despite the excitement surrounding the stock, Revolution Medicines was not included in The Motley Fool Stock Advisor's list of the top 10 stocks to buy, indicating ongoing uncertainty about its future performance in a competitive market.
See More
Revolution Medicines Updates Clinical Data on Daraxonrasib for Pancreatic Cancer
- Clinical Trial Update: Revolution Medicines has updated clinical data from two Phase 1/2 trials of Daraxonrasib in previously untreated metastatic pancreatic ductal adenocarcinoma patients, demonstrating manageable safety and tolerability, supporting further evaluation in first-line treatment.
- Combination Therapy Results: In the RMC-GI-102 trial, patients receiving Daraxonrasib combined with gemcitabine and nab-paclitaxel showed a confirmed objective response rate (ORR) of 58%, indicating significant antitumor activity, with a 6-month progression-free survival (PFS) estimate of 84%.
- Monotherapy Performance: In the RMC-6236-001 trial, Daraxonrasib monotherapy yielded an ORR of 47% and a disease control rate of 92%, with a 6-month PFS estimate of 71%, highlighting its potential in treating previously untreated RAS-mutant metastatic pancreatic cancer patients.
- Future Presentation Plans: The company plans to present the latest data from both the combination and monotherapy cohorts at the American Association for Cancer Research Annual Meeting on April 21, 2026, further validating the application prospects of Daraxonrasib in this high-mortality cancer.
See More
